SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-097073
Filing Date
2024-08-14
Accepted
2024-08-14 16:25:15
Documents
65
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q pyxs-20240630.htm   iXBRL 10-Q 2057114
2 EX-10.1 pyxs-ex10_1.htm EX-10.1 115059
3 EX-31.1 pyxs-ex31_1.htm EX-31.1 14803
4 EX-31.2 pyxs-ex31_2.htm EX-31.2 14808
5 EX-32.1 pyxs-ex32_1.htm EX-32.1 8675
6 EX-32.2 pyxs-ex32_2.htm EX-32.2 8032
7 GRAPHIC img32422092_0.jpg GRAPHIC 122064
  Complete submission text file 0000950170-24-097073.txt   7791960

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20240630.xsd EX-101.SCH 1322824
67 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20240630_htm.xml XML 917104
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

IRS No.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40881 | Film No.: 241208423
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)